Somnotouch-NIBP Compared to Standard Ambulatory 24-hours Blood Pressure Measurement
Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Recruiting
CT.gov ID
NCT03975582
Collaborator
(none)
300
1
34.9
8.6
Study Details
Study Description
Brief Summary
Comparison of 24 hours blood pressure measurement with puls-transit time versus cuffs.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Somnotouch-NIBP Compared to Standard Ambulatory 24 Hours Blood Pressure Measurement - a Prospective Registry
Actual Study Start Date
:
Jul 4, 2019
Anticipated Primary Completion Date
:
Jun 1, 2022
Anticipated Study Completion Date
:
Jun 1, 2022
Outcome Measures
Primary Outcome Measures
- Difference in mean 24 hours systolic blood pressure [24 hours]
Difference in mean 24 hours systolic blood pressure
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Age ≥ 18 years
-
Ability to give informed consent
Exclusion Criteria:
-
Age < 18 years
-
Medical reasons that forbid blood pressure measurements on upper extremities
-
Not able to give informed consent
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University Hospital Basel | Basel | Basel Stadt | Switzerland | 4031 |
Sponsors and Collaborators
- University Hospital, Basel, Switzerland
Investigators
- Principal Investigator: Thilo Burkard, MD, University Hospital, Basel, Switzerland
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT03975582
Other Study ID Numbers:
- VAST-Registry
First Posted:
Jun 5, 2019
Last Update Posted:
Nov 11, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No